Atea Pharmaceuticals Inc — Cash Flow (NASDAQ:AVIR) | MetaTrader

Open full chart

Financials

Overview Estratto Conto Statistics Dividends

Quarterly Annual

Cash from operating activities 296.73 M87 M120.98 M85.39 M135.5 M 134.21 M Cash from investing activities 26 K4 000455.41 M40.3 M56.1 M 138.83 M Cash from financing activities 531.75 M1.47 M370 K257 K267 K 25.75 M Free cash flow 296.71 M87 M119.04 M85.39 M135.5 M 134.21 M

Notizie

Atea Pharmaceuticals, Inc. (AVIR) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow (NASDAQ:AVIR) 2026-01-19

Atea Pharmaceuticals, Inc. (AVIR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Atea’s HCV treatment regimen phase 3 results expected mid-2026

Atea Pharmaceuticals: Best-In-Class HCV Cure With Pivotal Readouts In 2026 (NASDAQ:AVIR)

Atea completa l’arruolamento nel trial di fase 3 per il trattamento dell’HCV

Atea completes enrollment in HCV treatment phase 3 trial

Atea Pharmaceuticals, Inc. 2025 Q3 - Results - Earnings Call Presentation (NASDAQ:AVIR) 2025-11-14

Atea Pharmaceuticals, Inc. (AVIR) Q3 2025 Earnings Call Transcript

Cisco, Flutter, Manulife and more set to report earnings Wednesday

Il farmaco combinato di Atea per l’epatite C mostra risultati promettenti in uno studio di modellazione

Atea’s hepatitis C drug combination shows promising results in modeling study

Atea Pharmaceuticals Q2 2025 slides: HCV program advances with Phase 3 trials underway